Click a keyword to view all the abstracts on this site tagged with that keyword.
- juvenile dermatomyositis and polymyositis/dermatomyositis (PM/DM)
 - juvenile dermatomyositis and proteomics
 - juvenile dermatomyositis and pulmonary complications
 - juvenile dermatomyositis and race/ethnicity
 - juvenile dermatomyositis and remission
 - juvenile dermatomyositis and rituximab
 - juvenile dermatomyositis and scleroderma
 - juvenile dermatomyositis and skin
 - Juvenile dermatomyositis and treatment
 - juvenile dermatomyositis and vasculitis
 - Juvenile idiopathic arthritis
 - juvenile idiopathic arthritis (JIA)
 - juvenile idiopathic arthritis (JIA) and access to care
 - juvenile idiopathic arthritis (JIA) and administrative databases
 - juvenile idiopathic arthritis (JIA) and anti-TNF therapy
 - juvenile idiopathic arthritis (JIA) and juvenile idiopathic arthritis-enthesitis (ERA)
 - juvenile idiopathic arthritis (JIA) and juvenile myositis
 - juvenile idiopathic arthritis (JIA) and lipids
 - juvenile idiopathic arthritis (JIA) and longitudinal studies
 - Juvenile idiopathic arthritis (JIA) and macrophage activation syndrome
 - juvenile idiopathic arthritis (JIA) and magnetic resonance imaging (MRI)
 - Juvenile idiopathic arthritis (JIA) and major histocompatibility complex (MHC)
 - juvenile idiopathic arthritis (JIA) and malignancy
 - juvenile idiopathic arthritis (JIA) and meta-analysis
 - juvenile idiopathic arthritis (JIA) and methotrexate (MTX)
 - juvenile idiopathic arthritis (JIA) and microbiome
 - juvenile idiopathic arthritis (JIA) and monocytes
 - juvenile idiopathic arthritis (JIA) and musculoskeletal pain
 - juvenile idiopathic arthritis (JIA) and natural killer (NK) cells
 - juvenile idiopathic arthritis (JIA) and neutrophils
 - Juvenile idiopathic arthritis (JIA) and nonsteroidal antiinflammatory drugs (NSAIDs)
 - juvenile idiopathic arthritis (JIA) and nutrition
 - Juvenile idiopathic arthritis (JIA) and opportunistic infections
 - juvenile idiopathic arthritis (JIA) and oral
 - juvenile idiopathic arthritis (JIA) and outcome measures
 - Juvenile idiopathic arthritis (JIA) and outcomes
 - juvenile idiopathic arthritis (JIA) and ovarian
 - juvenile idiopathic arthritis (JIA) and pain
 - juvenile idiopathic arthritis (JIA) and pathogenesis
 - juvenile idiopathic arthritis (JIA) and patient
 - juvenile idiopathic arthritis (JIA) and patient outcomes
 - juvenile idiopathic arthritis (JIA) and patient preferences
 - Juvenile idiopathic arthritis (JIA) and patient-reported outcome measures
 - juvenile idiopathic arthritis (JIA) and pediatric rheumatology
 - juvenile idiopathic arthritis (JIA) and pediatrics
 - juvenile idiopathic arthritis (JIA) and physical activity
 - juvenile idiopathic arthritis (JIA) and physical function
 - juvenile idiopathic arthritis (JIA) and polyarthritis
 - juvenile idiopathic arthritis (JIA) and polymorphism
 - juvenile idiopathic arthritis (JIA) and population studies
 - juvenile idiopathic arthritis (JIA) and positron emission tomography (PET)
 - Juvenile idiopathic arthritis (JIA) and pregnancy
 - juvenile idiopathic arthritis (JIA) and prescribing trends
 - Juvenile idiopathic arthritis (JIA) and proteomics
 - juvenile idiopathic arthritis (JIA) and psoriasis
 - Juvenile idiopathic arthritis (JIA) and quality measures
 - juvenile idiopathic arthritis (JIA) and quality of life
 - Juvenile idiopathic arthritis (JIA) and race/ethnicity
 - juvenile idiopathic arthritis (JIA) and radiography
 - juvenile idiopathic arthritis (JIA) and registries
 - juvenile idiopathic arthritis (JIA) and registry
 - juvenile idiopathic arthritis (JIA) and regulatory cells
 - juvenile idiopathic arthritis (JIA) and remission
 - juvenile idiopathic arthritis (JIA) and rheumatoid arthritis (RA)
 - juvenile idiopathic arthritis (JIA) and safety
 - juvenile idiopathic arthritis (JIA) and self-management
 - Juvenile idiopathic arthritis (JIA) and shared dicision making
 - juvenile idiopathic arthritis (JIA) and spondylarthropathy
 - juvenile idiopathic arthritis (JIA) and statistical methods
 - juvenile idiopathic arthritis (JIA) and synovial cells
 - juvenile idiopathic arthritis (JIA) and synovial fluid
 - juvenile idiopathic arthritis (JIA) and synovitis
 - juvenile idiopathic arthritis (JIA) and systemic lupus erythematosus (SLE)
 - juvenile idiopathic arthritis (JIA) and T cell repertoire
 - juvenile idiopathic arthritis (JIA) and technology
 - Juvenile idiopathic arthritis (JIA) and temporomandibular joint
 - juvenile idiopathic arthritis (JIA) and therapy
 - juvenile idiopathic arthritis (JIA) and tocilizumab
 - juvenile idiopathic arthritis (JIA) and treatment
 - juvenile idiopathic arthritis (JIA) and treatment options
 - juvenile idiopathic arthritis (JIA) and tuberculosis
 - juvenile idiopathic arthritis (JIA) and tumor necrosis factor (TNF)
 - juvenile idiopathic arthritis (JIA) and ultrasonography
 - Juvenile idiopathic arthritis (JIA) and ultrasound
 - Juvenile idiopathic arthritis (JIA) and uveitis
 - juvenile idiopathic arthritis (JIA) and vaccines
 - Juvenile idiopathic arthritis-enthesitis (ERA)
 - juvenile idiopathic arthritis-enthesitis (ERA) and juvenile spondylarthropathy
 - juvenile idiopathic arthritis-enthesitis (ERA) and neutrophils
 - juvenile idiopathic arthritis-enthesitis (ERA) and oral
 - juvenile idiopathic arthritis-enthesitis (ERA) and outcome measures
 - Juvenile idiopathic arthritis-enthesitis (ERA) and outcomes
 - juvenile idiopathic arthritis-enthesitis (ERA) and pathogenesis
 - juvenile idiopathic arthritis-enthesitis (ERA) and pediatric rheumatology
 - juvenile idiopathic arthritis-enthesitis (ERA) and polyarthritis
 - juvenile idiopathic arthritis-enthesitis (ERA) and registry
 - juvenile idiopathic arthritis-enthesitis (ERA) and remission
 - juvenile idiopathic arthritis-enthesitis (ERA) and safety
 - juvenile idiopathic arthritis-enthesitis (ERA) and spondylarthritis
 - juvenile idiopathic arthritis-enthesitis (ERA) and synovial cells
 - juvenile idiopathic arthritis-enthesitis (ERA) and synovial fluid
 - juvenile idiopathic arthritis-enthesitis (ERA) and temporomandibular joint
 - Juvenile idiopathic arthritis-enthesitis (ERA) and treatment options
 - juvenile idiopathic arthritis-enthesitis (ERA) and tumor necrosis factor (TNF)
 - Juvenile Inflammatory Arthritis
 - juvenile myositis
 - juvenile myositis and myopathy
 - juvenile myositis and myositis
 - juvenile myositis and outcomes
 - juvenile myositis and pathogenesis
 - Juvenile myositis and patient engagement
 - juvenile myositis and pediatric rheumatology
 - juvenile myositis and prognostic factors
 - Juvenile Rheumatoid Arthritis
 - Juvenile Sacroiliitis
 - Juvenile scleroderma
 - juvenile scleroderma and juvenile idiopathic arthritis (JIA)
 - Juvenile scleroderma and juvenile sclerosis
 - juvenile scleroderma and morphea
 - juvenile scleroderma and myopathy
 - juvenile scleroderma and outcomes
 - Juvenile scleroderma and pediatric rheumatology
 - juvenile scleroderma and systemic sclerosis
 - Juvenile sclerosis
 - Juvenile sclerosis and pediatric rheumatology
 - juvenile sclerosis and Pulmonary Involvement
 - juvenile sclerosis and systemic sclerosis
 - juvenile SLE
 - juvenile SLE and activity score
 - juvenile SLE and genetics
 - juvenile SLE and Intervention
 - Juvenile SLE and morbidity and mortality
 - juvenile SLE and pediatric rheumatology
 - juvenile SLE and performance
 - juvenile SLE and randomized trials
 - juvenile SLE and renal disease
 - Juvenile SLE and systemic lupus erythematosus (SLE)
 - juvenile SLE and thrombocytopenia
 - juvenile spondylarthropathy
 - juvenile spondylarthropathy and juvenile arthritis
 - juvenile spondylarthropathy and pediatric rheumatology
 - juvenile spondylarthropathy and prognostic factors
 - juvenile spondylarthropathy and spondylarthropathy
 - Juvenile Spondyloarthritis
 - Kawasaki disease
 - Kawasaki disease and aspirin
 - Kawasaki disease and epidemiologic methods
 - Kawasaki disease and intravenous immunoglobulin (IVIG)
 - Kawasaki disease and Nail
 - Kawasaki disease and polymorphism
 - kENYA
 - keratinocyte
 - Keratinocytes
 - Kezar
 - kid
 - Kidney
 - Kidney and amyloidosis
 - Kidney and complement
 - Kidney and crystal-induced arthritis
 - Kidney and gout
 - Kidney and Plasmablasts
 - Kidney and rheumatoid arthritis (RA)
 - Kidney and Sjogren's syndrome
 - Kidney and SLE
 - Kidney and therapeutic targeting
 - Kidney and tumor necrosis factor (TNF)
 - Kidney and uric acid
 - kidney disease
 - Kidney function
 - Kidney stiffness
 - kidney transplant recipients
 - kinase
 - kinase and monocytes
 - kinase and mouse model
 - kinase and osteoclasts
 - kinase and rheumatoid arthritis
 - kinase and rheumatoid arthritis (RA)
 - kinase and rheumatologic disease
 - kinase and signal transduction
 - kinase and syk
 - kinase and systemic sclerosis
 - KIR (Killer Ig like receptor)
 - KL-6 and pulmonary function test
 - KLRG1
 - Knee
 - Knee and arthrocentesis
 - Knee and cartilage
 - Knee and clinical trials
 - Knee and epidemiology
 - Knee and health care cost
 - Knee and Hip
 - Knee and injury
 - Knee and meniscus
 - Knee and MRI
 - Knee and OA
 - Knee and osteoarthritis
 - Knee and pain
 - Knee and physical activity
 - Knee OA and Molecular weight
 - Knee osteoarthritis
 
